All Updates

All Updates

icon
Filter
M&A
Biogen to acquire Human Immunology Biosciences for USD 1.15 billion to expand its pipeline
Precision Medicine
May 22, 2024
Last week:
Geographic expansion
Partnerships
Lemonade partners with Homesite to expand home insurance services
InsurTech: Personal Lines
Jun 14, 2024
Funding
BayaniPay raises USD 3 million in seed funding to expand payment solutions
Neobanks
Jun 14, 2024
Partnerships
Carbonfuture and Swiss Re partner for long-term carbon removal through biochar
Carbon Management Software
Jun 13, 2024
Funding
Sidekick raises GBP 8.5 million in seed and debt funding to support expansion
Retail Trading Infrastructure
Jun 13, 2024
Partnerships
Climatiq and Epicor partner to reduce CO2 emissions in supply chains
Carbon Management Software
Jun 13, 2024
Product updates
EHang's pilotless eVTOL aircraft concludes first flight launch in Saudi Arabia
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Skyports partners with Unified Aviation to accelerate global network release
Passenger eVTOL Aircraft
Jun 13, 2024
Industry news
Partnerships
USSF chooses Blue Origin, SpaceX, and ULA for ~USD 5.6 billion Pentagon launch contracts
Space Travel and Exploration Tech
Jun 13, 2024
Funding
AnyCreek raises USD 1.8 million in seed funding to enhance platform and expand into new markets
Travel Tech
Jun 13, 2024
Funding
Zeta Labs raises USD 2.9 million in pre-seed funding to develop autonomous AI agent
Generative AI Applications
Jun 13, 2024
Precision Medicine

Precision Medicine

May 22, 2024

Biogen to acquire Human Immunology Biosciences for USD 1.15 billion to expand its pipeline

M&A

  • Biogen has announced the acquisition of Human Immunology Biosciences (HI-Bio), a biotechnology firm specializing in providing targeted therapies for severe immune-mediated diseases. The transaction was valued at USD 1.15 billion, with potential milestone payments up to USD 650 million. The acquisition is planned to be finalized in the third quarter of 2024.

  • Post-acquisition, Biogen will gain ownership of HI-Bio’s lead candidate felzartamab, a late-stage asset for renal diseases. Biogen aims to combine HI-Bio’s expertise with its own resources to further develop this program as well as develop novel therapies. The candidate has been granted FDA breakthrough therapy designation and orphan drug designation for the treatment of primary membranous nephropathy.

  • Biogen is a biotechnology company specializing in the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases. Biogen's portfolio includes treatments for multiple sclerosis such as Avonex, Tysabri, Tecfidera, and Vumerity. The company also markets Spinraza for spinal muscular atrophy and Aduhelm for Alzheimer's disease.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.